Kwality Pharmaceuticals profit and loss

Latest FY24

Revenue: ₹307cr+22.4% on FY23
EBITDA: ₹66.6cr+10.5% on FY23

₹ crore except per share

Tap a line for its trend	FY24Mar 2024	FY23Mar 2023	FY22Mar 2022

Expenses
	307	251	456
	—	—	460
	154	113	199
	0.9	0.0	3.8
	−1.5	−3.2	−2.5
	32.5	29.9	20.1
	10.4	6.0	2.9
	19.5	14.9	10.6
	270	212	298
	66.6	60.3	172
	47.1	45.4	161
Profit
	31.5	25.8	162
	—	6.5	41.0
	—	0.1	0.3
	—	—	41.3
	—	—	120
	—	−0.3	—
Per share
	—	₹18.45	₹115.70
	—	₹18.45	₹115.70
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	154	141	256
	50.1%	56.1%	56.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

KPL₹3,696.70

Kwality Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersBPLPHARMA JENBURPH MAKERSL NOVARTIND PARNAXLAB SGRL SHUKRAPHAR SUNLOC

View

In ₹ Crore except Per Share 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024
Revenue from Operations	456.1	251.0	307.2
Total Income	459.6	—	—
Expenses
+ Cost of Materials Consumed	199.3	113.2	153.8
+ Purchases of Stock-in-Trade	3.8	0.0	0.9
+ Changes in Inventories	-2.5	-3.2	-1.5
+ Employee Benefit Expense	20.1	29.9	32.5
+ Finance Costs	2.9	6.0	10.4
+ Depreciation & Amortisation	10.6	14.9	19.5
Total Expenses	298.0	211.6	270.4
EBITDA	171.7	60.3	66.6
EBIT	161.1	45.4	47.1
Profit
Pretax Income	161.7	25.8	31.5
+ Current Tax	41.0	6.5	—
+ Deferred Tax	0.3	0.1	—
Tax Expense	41.3	—	—
Net Income	120.0	—	—
+ Other Comprehensive Income	—	-0.3	—
Per Share
Basic EPS	115.70	18.45	—
Diluted EPS	115.70	18.45	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	255.5	140.9	154.0
Gross Margin %	56.02	56.15	50.13

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.